Nuvalent (NUVL) Interest Expenses (2020 - 2026)
Nuvalent (NUVL) posted Interest Expenses of $465.5 million for Q1 2026, down 2.28% on a QoQ basis from $476.4 million in Q4 2025, and up 39.27% year-over-year from $334.3 million in Q1 2025.
Nuvalent (NUVL) Interest Expenses (2020 - 2026) Analysis & Trends
Nuvalent's Interest Expenses history runs 7 years deep, the most recent figure standing at $465.5 million for Q1 2026.
- Quarterly Interest Expenses rose 39.27% year-over-year to $465.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $465.5 million (up 39.27% YoY) and the FY2025 annual result came in at $476.4 million, up 19.56% from the prior year.
- Interest Expenses was $465.5 million for Q1 2026 at Nuvalent, down from $476.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $617.6 million in Q3 2024 and bottomed at $512000.0 in Q1 2023.
- A 5-year average of $233.6 million and a median of $334.3 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 94.25% — and 2024, when it surged 47044.12%.
- Nuvalent's Interest Expenses stood at $1.3 million in 2022, then jumped by 33312.86% to $449.4 million in 2023, then slipped by 11.35% to $398.4 million in 2024, then climbed by 19.56% to $476.4 million in 2025, then fell by 2.28% to $465.5 million in 2026.
- Business Quant data shows NUVL's Interest Expenses at $465.5 million in Q1 2026, $476.4 million in Q4 2025, and $428.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 465.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 465.51 Mn |
| Mar 31, 2026 | 465.51 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Sep 30, 2025 | 428.90 Mn |
| Sep 30, 2025 | 428.90 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Mar 31, 2025 | 334.26 Mn |
| Mar 31, 2025 | 334.26 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Sep 30, 2024 | 617.59 Mn |
| Sep 30, 2024 | 617.59 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 449.40 Mn |
| Dec 31, 2023 | 449.40 Mn |